The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
Open accessAbstract
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Self-citation(1965) · The Lancet · doi:10.1016/s0140-6736(65)91037-8 · Cited by 16,856
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Self-citationRevised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Self-citationReport of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Coiffier, B., Osmanov, E. A., Hong, X., Scheliga, A. A. D. S., Mayer, J., Offner, F. C., Rule, S. A., Teixeira, A., Walewski, J. A., de Vos, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70150-4 · Cited by 2,741
Self-citationAppio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citationBarrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665
Self-citationIbrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Self-citationKochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Self-citationYounes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Self-citationJuweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2305 · Cited by 1,335
Self-citationApplied Smoothing Techniques for Data Analysis: The Kernel Approach with S-PLUS Illustrations
Kafadar, K., Bowman, A. W., & Azzalini, A. (1999) · Journal of the American Statistical Association · doi:10.2307/2670015 · Cited by 1,193
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×
“In many cases of chronically administered new agents, including immune therapies, the best response to treatment may only be achieved after prolonged administration of therapy [35, 36].”
Self-citationSalles, G., Seymour, J. F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,079
Self-citationPI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
Self-citationTurtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016
Younes, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J. M., Ansell, S., Armand, P., Fanale, M., Ratanatharathorn, V., Kuruvilla, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30167-x · Cited by 927
Self-citationFederico, M., Bellei, M., Marcheselli, L., Luminari, S., Lopez-Guillermo, A., Vitolo, U., Pro, B., Pileri, S., Pulsoni, A., Soubeyran, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3991 · Cited by 751
Self-citationHodi, F. S., Hwu, W.-J., Kefford, R., Weber, J. S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 734
Armand, P., Shipp, M. A., Ribrag, V., Michot, J.-M., Zinzani, P. L., Kuruvilla, J., Snyder, E. S., Ricart, A. D., Balakumaran, A., Rose, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3467 · Cited by 670
Self-citationBrown, J. R., Byrd, J. C., Coutre, S. E., Benson, D. M., Flinn, I. W., Wagner-Johnston, N. D., Spurgeon, S. E., Kahl, B. S., Bello, C., Webb, H. K., et al. (2014) · Blood · doi:10.1182/blood-2013-11-535047 · Cited by 590
Cheson, B. D., Ansell, S., Schwartz, L., Gordon, L. I., Advani, R., Jacene, H. A., Hoos, A., Barrington, S. F., & Armand, P. (2016) · Blood · doi:10.1182/blood-2016-05-718528 · Cited by 521
Self-citationBollard, C. M., Gottschalk, S., Torrano, V., Diouf, O., Ku, S., Hazrat, Y., Carrum, G., Ramos, C., Fayad, L., Shpall, E. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.5304 · Cited by 503
Self-citationDreyling, M., Jurczak, W., Jerkeman, M., Silva, R. S., Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Harig, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00667-4 · Cited by 463
Self-citationWitzig, T. E., Vose, J. M., Zinzani, P. L., Reeder, C. B., Buckstein, R., Polikoff, J. A., Bouabdallah, R., Haioun, C., Tilly, H., Guo, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq626 · Cited by 392
Self-citationGoy, A., Sinha, R., Williams, M. E., Kalayoglu Besisik, S., Drach, J., Ramchandren, R., Zhang, L., Cicero, S., Fu, T., & Witzig, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2835 · Cited by 349
Self-citationvan Oers, M. H. J., Van Glabbeke, M., Giurgea, L., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., van t Veer, M., Vranovsky, A., Holte, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5827 · Cited by 328
Self-citationEvaluation of lymph nodes with RECIST 1.1
Schwartz, L. H., Bogaerts, J., Ford, R., Shankar, L., Therasse, P., Gwyther, S., & Eisenhauer, E. A. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.028 · Cited by 298
Self-citationEl-Galaly, T. C., d'Amore, F., Mylam, K. J., de Nully Brown, P., Bøgsted, M., Bukh, A., Specht, L., Loft, A., Iyer, V., Hjorthaug, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.4036 · Cited by 295
Self-citationFriedman, D. L., Chen, L., Wolden, S., Buxton, A., McCarten, K., FitzGerald, T. J., Kessel, S., De Alarcon, P. A., Chen, A. R., Kobrinsky, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.5410 · Cited by 269
Younes, A., Sureda, A., Ben-Yehuda, D., Zinzani, P. L., Ong, T.-C., Prince, H. M., Harrison, S. J., Kirschbaum, M., Johnston, P., Gallagher, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.1350 · Cited by 263
Self-citationWitzig, T. E., Wiernik, P. H., Moore, T., Reeder, C., Cole, C., Justice, G., Kaplan, H., Voralia, M., Pietronigro, D., Takeshita, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1169 · Cited by 260
Self-citationAnalysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables
Anderson, J. R., Cain, K. C., & Gelber, R. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1000 · Cited by 228
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
Younes, A., Oki, Y., Bociek, R. G., Kuruvilla, J., Fanale, M., Neelapu, S., Copeland, A., Buglio, D., Galal, A., Besterman, J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70265-0 · Cited by 196
Self-citationHerman, S. E. M., Niemann, C. U., Farooqui, M., Jones, J., Mustafa, R. Z., Lipsky, A., Saba, N., Martyr, S., Soto, S., Valdez, J., et al. (2014) · Leukemia · doi:10.1038/leu.2014.122 · Cited by 193
When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival
Panageas, K. S., Ben-Porat, L., Dickler, M. N., Chapman, P. B., & Schrag, D. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk091 · Cited by 182
Adams, H. J. A., Kwee, T. C., de Keizer, B., Fijnheer, R., de Klerk, J. M. H., & Nievelstein, R. A. J. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2623-4 · Cited by 167
The International Harmonization Project for Response Criteria in Lymphoma Clinical Trials
Cheson, B. D. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.06.011 · Cited by 132
When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression
Oxnard, G. R., Morris, M. J., Hodi, F. S., Baker, L. H., Kris, M. G., Venook, A. P., & Schwartz, L. H. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs353 · Cited by 129
Self-citationEvens, A. M., Balasubramanian, S., Vose, J. M., Harb, W. A., Gordon, L. I., Langdon, R. M., Sprague, J. R., Sirisawad, M., Mani, C., Yue, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0624 · Cited by 103
Fiorcari, S., Brown, W. S., McIntyre, B. W., Estrov, Z. E., Maffei, R., O'Brien, S. M., Sivina, M., Hoellenriegel, J., Wierda, W. G., Keating, M. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083830 · Cited by 98
Chanan-Khan, A. A., Miller, K. C., Lawrence, D. D., Padmanabhan, S., Miller, A., Hernandez‐Illatazurri, F., Czuczman, M. S., Wallace, P. K., Zeldis, J. B., & Lee, K. P. (2010) · Cancer · doi:10.1002/cncr.25748 · Cited by 88
Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson
Fournier, L. S., Ammari, S., Thiam, R., & Cuénod, C. A. (2014) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2014.05.002 · Cited by 83
Pelosi, E., Penna, D., Douroukas, A., et al. (2011) · PubMed · Cited by 78
The landscape of new drugs in lymphoma
Younes, A., Ansell, S. M., Fowler, N. H., Wilson, W. H., de Vos, S., Seymour, J. F., Advani, R. H., Forero, A., Morschhauser, F., Kersten, M. J., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.205 · Cited by 76
Self-citationPark, J. H., & Brentjens, R. J. (2010) · PubMed · Cited by 67
Hoos, A., Wolchok, J. D., Humphrey, R. W., & Hodi, F. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3128 · Cited by 64
Lymphocytosis and ibrutinib treatment of CLL
Rossi, D., & Gaïdano, G. (2014) · Blood · doi:10.1182/blood-2014-01-549493 · Cited by 26
Ibrutinib‐associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma
Furtado, M., Wang, M. L., Munneke, B., McGreivy, J. S., Beaupre, D. M., & Rule, S. A. (2015) · British Journal of Haematology · doi:10.1111/bjh.13275 · Cited by 19
Self-citationZinzani, P. L., Ribrag, V., Moskowitz, C. H., Michot, J., Kuruvilla, J. G., Balakumaran, A., Snyder, E., Marinello, P. M., Shipp, M. A., & Armand, P. A. (2015) · Blood · doi:10.1182/blood.v126.23.3986.3986 · Cited by 19
Self-citation
Cited by
Armand, P., Engert, A., Younes, A., Fanale, M., Santoro, A., Zinzani, P. L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J. B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0793 · Cited by 759
Self-citationIbrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Tam, C. S., Anderson, M. A., Pott, C., Agarwal, R., Handunnetti, S., Hicks, R. J., Burbury, K., Turner, G., Di Iulio, J., Bressel, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715519 · Cited by 433
Self-citationKanate, A. S., Majhail, N. S., Savani, B. N., Bredeson, C., Champlin, R. E., Crawford, S., Giralt, S. A., LeMaistre, C. F., Marks, D. I., Omel, J. L., et al. (2020) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2020.03.002 · Cited by 283
Carbone, A., Roulland, S., Gloghini, A., Younes, A., von Keudell, G., López-Guillermo, A., & Fitzgibbon, J. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0132-x · Cited by 278
Self-citationClinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
Kotlov, N., Bagaev, A., Revuelta, M. V., Phillip, J. M., Cacciapuoti, M. T., Antysheva, Z., Svekolkin, V., Tikhonova, E., Miheecheva, N., Kuzkina, N., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0839 · Cited by 267
Self-citation
Metadata
- Authors
- Younes, A., Hilden, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., Seymour, J. F., Kelly, K., Gribben, J., Pfreunschuh, M., Morschhauser, F., Schoder, H., Zelenetz, A. D., Rademaker, J., Advani, R., Valente, N., Fortpied, C., Witzig, T. E., Sehn, L. H., Engert, A., Fisher, R. I., Zinzani, P.-L., Federico, M., Hutchings, M., Bollard, C., Trneny, M., Elsayed, Y. A., Tobinai, K., Abramson, J. S., Fowler, N., Goy, A., Smith, M., Ansell, S., Kuruvilla, J., Dreyling, M., Thieblemont, C., Little, R. F., Aurer, I., Van Oers, M. H. J., Takeshita, K., Gopal, A., Rule, S., de Vos, S., Kloos, I., Kaminski, M. S., Meignan, M., Schwartz, L. H., Leonard, J. P., Schuster, S. J., & Seshan, V. E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 28
- Issue
- 7
- Pages
- 1436-1447
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2604580699
- Cited by
- 369
- References
- 56
- FWCI
- 17.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.